WELCOME TO The Biotechnology REPORT
PCR (Phylasis Clinicas Research)
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Cell and Gene Therapy, Industrial Impact
Ligand Pharmaceuticals | February 21, 2023
In a recent announcement by biopharmaceutical firm, Ligand Pharmaceuticals, the U.S. Food and Drug Administration (FDA) has given accelerated approval for FILSPARITM (sparsentan). This will be helpful in treating adults with primary IgAN condition who are at risk of rapid disease progression, typically defined as a urine protein-to-creatinine ratio (UPCR) of less than 1.5 g/g.
FILSPARI, a once-daily oral medicine, is the first and only non-immunosuppressive therapy authorized fo...
Carbosynth | May 30, 2022
Biosynth Carbosynth (“Biosynth”), a supplier of critical materials to the life science industry, announces today the acquisition of Aalto Bio Reagents (“Aalto”), a leading developer and provider of biological materials to the in-vitro diagnostic (IVD) and vaccine development industry in the field of emerging disease.
The acquisition represents a further milestone in Biosynth’s development, which broadens its capabilities and offering to the IVD indust...
Cell and Gene Therapy
iXCells Biotechnologies | September 30, 2022
iXCells Biotechnologies a high growth provider of cell-based products and discovery services to the academic, biotech and pharmaceutical communities worldwide, with special focus on primary and induced pluripotent stem cell derived cellular models, today announced receiving a growth investment from Connecticut-based Great Point Partners a private investment firm focusing on the healthcare industry.
“iXCells is delighted to join GPP’s portfolio of ...
Salipro Biotech | September 08, 2022
Salipro Biotech AB, a Swedish biotech company with a leading technology platform for the stabilization of membrane proteins for drug development, announced today that its patent entitled "Saposin lipoprotein particles and libraries from crude membranes" has been issued by both the U.S. Patent and Trademark Office and by the China National Intellectual Property Administration. The patents cover the company's novel method of direct extraction of membrane proteins from cells or crude ...
Industrial Impact, Medical
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE